Table III.

miR-126 as a potential target for lung cancer therapy.

A, Methods targeting miRNA-126
Expression of miR-126	Experimental setting	Targets	Effects	(Refs.)
Upregulated	In vitro, in vivo	EGFL7	Inhibition on initiating cell differentiation, tumour cells proliferation and tumor formation	(40)
Upregulated	In vitro, in vivo	PI3K/AKT/Snail	Inhibition on lung cancer metastasis, EMT	(27)
Upregulated	In vitro	VEGF/PI3K/AKT/MRP1	Promoting the sensitivity of NSCLC cells to anticancer agents	(3)
Upregulated	In vivo	PI3K-AKT	Promoting ionizing radiation-induced apoptosis	(79,80)
B, Methods using miR-126 differently
Expression of miR-126	Experimental setting	Targets	Effects	(Refs.)
lncRNA-PVT1-5/ miR-126	In vitro	SLC7A5	Inhibition on tumorigenesis	(81)
miR-126-231-Exo	In vitro, in vivo	PTEN/PI3K/AKT	Inhibition on tumorigenesis	(82)
C, Other drugs/methods
Expression of miR-126	Experimental setting	Targets	Effects	(Refs.)
Cryptotanshinone	In vitro	STAT3	Inhibition of the growth of lung cancer cells	(16)
TBMS1	In vitro	VEGF-A/VEGFR-2/ERK	Pro-apoptosis, anti-metastasis	(17)
CT-PRFA	In vivo	–	Inhibition of tumorigenesis	(88)

EGFL7, epidermal growth factor-like domain-containing gene 7; PI3K, phosphatidylinositol-3; AKT, protein kinase B; EMT, epithelial-mesenchymal transition; NSCLC, non-small cell lung cancer; VEGF, vascular endothelial growth factor; MRP1, resistance-associated protein 1; lncRNA-PVT1-5, long non-coding RNA-PVT1-5; SLC7A5, solute carrier family 7 (cationic amino acid transporter, y+ system), member 5; miR-126-231-Exo, miR-126 loaded into 231-Exo; PTEN, phosphatase and tensin homologue; STAT3, signal transducer and activator of transcription 3; TBMS1, tubeimoside-1; VEGF-A, vascular endothelial growth factor A; VEGFR-2, vascular endothelial growth factor receptor 2; ERK, extracellular protein kinase; CT-PRFA, computed tomography-guided percutaneous radio frequency ablation, miRNA, microRNA.